May SVAAII Main Event with John McCamant and Kevin T. Carter

DETAILS:
We welcome:
John McCamant, Editor, Medical Technology Stock Letter, https://bioinvest.com
John McCamant is editor of the Medical Technology Stock Letter. He has more than 35 years of experience in biotechnology investing. McCamant is frequently quoted in the financial press. Before becoming editor of the Medical Technology Stock Letter, McCamant worked as an equities analyst in the investment banking and venture capital industry.

Kevin T. Carter, Founder & Chief Investment Officer of EMQQ Global, https://www.emqqglobal.com
Kevin T. Carter is the Founder & Chief Investment Officer of EMQQ Global. While he principally considers himself an active “value” investor, he has collaborated with Princeton economist and indexing legend, Dr. Burton G. Malkiel, for more than 20 years. Together Malkiel and Carter founded eInvesting in 1999, a pioneer firm in fractional share brokerage acquired by ETRADE in 2000, and Active Index Advisors, a pioneer in “direct indexing” acquired by Natixis Asset Management in 2005. In 2006, their efforts turned to China and Emerging Markets, and they launched several China focused ETFs on the NYSE with Guggenheim Partners.

Click to Register here:
https://us02web.zoom.us/j/86533252502

Click to Donate here:
Silicon Valley AAII offers this Webinar for free and encourages those who can to donate $5 or $10 to help us cover costs for our hosting services.
https://www.eventbrite.com/e/may-main-event-1-top-picks-in-biotech-2-future-of-emerging-markets-tickets-881380130697

ATTEND THIS MEETING TO LEARN:
TOPIC 1: 2024 Top Picks in BioTech
John McCamant, Editor, Medical Technology Stock Letter, https://bioinvest.com
The Medical Technology Stock Letter has a proven track record of identifying biotech winners like Viking Therapeutics (VKTX) which recently soared and was easily the top performer in our 2024 Top Picks. John McCamant will help you navigate the election-year drug-pricing rhetoric to find more biotech winners. John will also help you understand the largest drug market, GLP-1s for Type 2 diabetes/obesity, and the best investment opportunities.
ATTEND THIS MEETING TO LEARN:
1. Biotech is part of the solution for healthier living and future disease threats.
2. Election-year drug-pricing rhetoric
3. Specific stock picks
SPEAKER’S BIOGRAPHY:
John McCamant is editor of the Medical Technology Stock Letter. He has more than 35 years of experience in biotechnology investing. McCamant is frequently quoted in the financial press. Before becoming editor of the Medical Technology Stock Letter, McCamant worked as an equities analyst in the investment banking and venture capital industry.

TOPIC 2: The Future of Emerging Markets & The Rise of a Digital India
Kevin T. Carter, Founder & Chief Investment Officer of EMQQ Global, https://www.emqqglobal.com
The Third Wave of global digitization has reached an inflection point. The conditions and technologies born in Silicon Valley have now spread, evolved, and matured worldwide, creating billions of digital natives and numerous unicorns in all corners of the globe. This confluence of forces has become most powerful in India. A thriving economy and favorable demographics are creating a digital golden age that’s expected to propel the country to the third largest economy by 2027.
ATTEND THIS MEETING TO LEARN:
1. What makes India the ideal emerging market?
2. Is India like China 15 years ago?
3. India's Economic secret weapon - understanding the power of the India Stack
4. How to invest in India's digital transformation
5. Next Wave of the Digital Revolution: LatAm and SE Asia
SPEAKER’S BIOGRAPHY:
Kevin T. Carter is the Founder & Chief Investment Officer of EMQQ Global. While he principally considers himself an active “value” investor, he has collaborated with Princeton economist and indexing legend, Dr. Burton G. Malkiel, for more than 20 years. Together Malkiel and Carter founded eInvesting in 1999, a pioneer firm in fractional share brokerage acquired by ETRADE in 2000, and Active Index Advisors, a pioneer in “direct indexing” acquired by Natixis Asset Management in 2005. In 2006, their efforts turned to China and Emerging Markets, and they launched several China focused ETFs on the NYSE with Guggenheim Partners.